Protara Therapeutics, Inc. cotiza a 2.62 USD y tiene una capitalización bursátil de $147M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladd…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.31 | $-0.38 |
| Estimado | $-0.33 | $-0.31 | $-0.37 | $-0.31 |
| Sorpresa | — | — | +16.2% | -22.6% |
| Métrica | TARA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -29.2% | -40.4% | +11.2% |
| ROA | -27.4% | -32.0% | +4.6% |
| Current Ratio | 14.58 | 2.84 | +11.74 |
| Debt / Equity | — | 0.28 | — |